세르골렉스올레

Sergolexole
세르골렉스올레
Sergolexole structure.png
식별자
  • (4-methoxyclonohexyl)(6aR,9R,10aR)-7-methyl-4-propan-2-yl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-9-carboxylate.
CAS 번호
펍켐 CID
유니
CompTox 대시보드 (EPA)
화학 및 물리적 데이터
공식C26H36N2O3
어금질량424.585 g·190−1
3D 모델(JSmol)
  • CC(C)N1C=C2C=C2C[C@@H]3[C@H](CN3C)C(=O)OC4CC(=O)C5=C2C1=CC5]C5
  • InChI=1S/C26H36N2O3/c1-16(2)28-15-17-13-24-22(21-6-5-7-23(28)25(17)21)12-18(14-27(24)3)26(29)31-20-10-8-19(30-4)9-11-20/h5-7,15-16,18-20,22,24H,8-14H2,1-4H3/t18-,19?,20?,22-,24-/m1/s1
  • 키:RJBJIKXTJIZONR-FTNAIZGWSA-N

Sergolexole(개발 코드명 LY-281,067)은 세로토닌 5-HT2 수용체선택적 길항제 역할을 하는 에르골린 유도체다. 다양한 연구 용도에 사용되어 왔지만, 의학용으로 개발된 적은 없다.[1][2][3]

참조

  1. ^ Cohen ML, Fuller RW, Kurz KD, Parli CJ, Mason NR, Meyers DB, et al. (January 1988). "Preclinical pharmacology of a new serotonergic receptor antagonist, LY281067". The Journal of Pharmacology and Experimental Therapeutics. 244 (1): 106–12. PMID 3335993.
  2. ^ Cohen ML, Parli CJ, Fuller RW (December 1989). "5-Hydroxytryptamine2 receptor antagonist activity of the acid metabolite (1-isopropyl dihydrolysergic acid) of the ergoline ester, sergolexole (LY281067)". The Journal of Pharmacology and Experimental Therapeutics. 251 (3): 1006–11. PMID 2600800.
  3. ^ Koba S, Pakala R, Watanabe T, Katagiri T, Benedict CR (November 1999). "Vascular smooth muscle proliferation: synergistic interaction between serotonin and low density lipoproteins". Journal of the American College of Cardiology. 34 (5): 1644–51. doi:10.1016/s0735-1097(99)00349-6. PMID 10551718.